Anti-viral lotion tissue and methods for making and using the same

ABSTRACT

A soothing anti-viral lotion composition and a lotioned tissue product having a surface with the lotion composition applied thereto, and methods for making and using the same. The lotion composition includes an anti-viral organic acid and a topical delivery system. The topical delivery system includes one or more hydroxyl-functional polyester diols which allow incorporation of the organic acids into the lotion formulation, controls their delivery, and maintains them in the stratum corneum. The lotion composition may optionally contain a surfactant, an irritation inhibiting agent, and other additives.

RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.09/753,136, entitled “Anti-Viral Tissue, and Methods for Making andUsing the Same,” filed on Dec. 29, 2000, which claims priority to U.S.App. Ser. No. 60/173,830, entitled, “Anti-Viral Lotion Tissue, andMethods for Making and Using the Same,” filed Dec. 30, 1999, the entiredisclosures of which are incorporated herein by reference.

FIELD OF THE INVENTION

The present invention relates generally to anti-viral lotion compositionand a lotioned tissue having anti-viral properties. More specifically,the present invention relates to a composition and a lotioned tissueincluding a surface having an anti-viral organic acid and a topicaldelivery system applied thereto, and methods for making and using thesame.

BACKGROUND

Various types of anti-viral tissues are known in the art. U.S. Pat. No.5,830,487, issued to Klofta et al., discloses a lotioned tissue paperhaving an anti-viral lotion composition that is a semi-solid or solid at20° C. The lotion comprises an organic acid, a hydrophilic solvent, anemollient, an immobilizing agent, a nonionic surfactant, an oil andother additives.

U.S. Pat. No. 5,705,164, issued to Mackey et al., discloses a tissuepaper having a lotion composition that is a solid or semisolid at roomtemperatures. The lotion composition may include an emollient,preferably a liquid polyol polyester, used to soften, sooth, ormoisturize the skin, and may include oils and fatty alcohols, and animmobilizing agent which also may contain polyesters. Other optionalcomponents include water, skin soothing agents, or anti-inflammatoriessuch as aloe vera or panthenol, and disinfectant antibacterial actives.

U.S. Pat. No. 5,871,763, issued to Luu et al., discloses substrates suchas a tissue or towel which are treated with a lotion. The lotionprovides a smooth feel that is lubricious and nongreasy, and is a solidat room temperature. The lotion may include an emollient such as a fat,oil, phospholipid, silicone, esters, or mixtures of esters; a retentionagent; conventional surfactants, including cationic surfactants;anti-viral agents, including organic acids, a fragrance, a powder, anextract; and/or a humectant.

U.S. Pat. No. 5,720,966, issued to Ostendorf, discloses a tissue paperhaving a semisolid therapeutic composition comprising a medicinalcomponent such as a virucide, disinfectant or analgesic and a lotion,which preferably includes mineral oil, paraffin wax, cetearyl alcohol,aloe extract and steareth-2.

U.S. Pat. No. 5,049,440, issued to Bornhoeft, III et al., discloses awet wiper having a liquid preservative composition including water, anaturally occurring organic acid and a naturally occurring salt. The wetwipe may also contain fragrances and skin moisturizers such asglycerine, aloe vera, lecithin, lanolin, and lanolin derivatives.

U.S. Pat. No. 4,772,501, issued to Johnson et al., discloses a wet wipeproduct in the form of a fibrous wipe. The wipe has a liquidpreservative composition having a mixture of citric and sorbic acids,and other optional components such as water, skin moisturizers, andfragrances.

U.S. Pat. No. 4,908,262, issued to Nelson, discloses toilet seat coverssuch as a fibrous sheet in which microencapsulated particles ofwater-soluble salts, preferably copper salts, and water-soluble ene-diolcompounds are entrained. The ene-diol compounds include dihydroxymaleicacid, ascorbic acid and compounds thereof, squaric acid anddehydroxyfumaric acid.

U.S. Pat. No. 5,869,075, issued to Kryzik, discloses a soft tissueproduct having a hydrophilic composition applied to its surface. Thecomposition includes a polyethylene glycol, a fatty alcohol, andlipophilic emollients. The composition may also include anti-microbialagents or other additives, such as skin exfoliating agents (alphahydroxy acids) and cationic surfactants.

U.S. Pat. Nos. 4,828,912 and 4,897,304, both issued to Hossain et al.,pertain to the use of a carboxylic acid/surfactant virucidal compositionfor use in absorbent products. U.S. Pat. Nos. 4,764,418 and 4,824,689,both issued to Kuenn et al., pertain to the addition of water-solublehumectants to carboxylic acid/surfactant virucides for use in tissueproducts to reduce irritation potential. U.S. Pat. No. 4,738,847 issuedto Rothe et al., pertains to adding a carboxylic acid/surfactantvirucide to the center ply of a three ply tissue to prevent the transferof the virucidal composition to the user, and thereby reduce irritationpotential.

Despite attempts made in a number of products, irritation caused byanti-viral organic acids in tissue products remains a persistentproblem.

SUMMARY

Therefore, there continues to be a need for improvements to lotionedtissues. The present invention provides lotion compositions and tissueproducts that are effective in killing viruses, but do not irritate theskin.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention concerns an improved lotion composition forapplication to a tissue product, and tissue products having the lotioncomposition applied to one or more surfaces thereof. The presentinvention is suitable for making tissue products such as facial tissues,bathroom tissues, table napkins, paper towels, and the like.

The present invention also concerns a method of preventing the spread ofa viral infection by providing anti-viral lotion tissue product havingthe lotion composition applied thereto. The user contacts the tissueproduct to a body part, such as the nose, and some of the lotion istransferred to the user. A fluid containing at least one virus, such asa nasal discharge, is absorbed into the tissue. The anti-viral organicacid contacts the lotion composition on both the tissue and on theuser's skin, and the virus is acted upon by the virucide in the lotioncomposition.

The lotion compositions of the present invention comprise an anti-viralorganic acid and a topical delivery system or emollient comprising oneor more polyesters. The topical delivery system allows incorporation ofthe acids into the lotion formulation, controls their delivery, andmaintains them in the stratum corneum. This reduces the amount of acidnecessary for efficacy, and thereby reduces the potential forirritation. Optional components include surfactants, irritationinhibiting agents, and additives such as oils, waxes, fatty alcohols,humectants, and the like. Each one of these components will be discussedin turn:

1. Anti-Viral Organic Acids

The anti-viral organic acids of the present invention are generallysolids or semi-solids at room temperature. Preferred anti-viral organicacids comprise at least one member selected from the group consisting ofcarboxylic acids having the structure R—COOH, wherein R is a C₁-C₆alkyl; C₁-C₆ alkyl carboxy; C₁-C₆ alkyl carboxyhydroxy; C₁-C₆ alkylcarboxy halo; C₁-C₆ alkylcarboxy dihydroxy; C₁-C₆ alkyldicarboxyhydroxy; C₁-C₆ lower alkenyl; C₁-C₆ alkenyl carboxy; C₁-C₆alkenyl phenyl; or substituted phenyl radical. Especially preferredcarboxylic acids are citric, malic, adipic, glutaric, and succinic acidsand mixtures thereof. In the above compounds one or more of the hydrogenatoms may be substituted by halogen atoms, hydroxyl groups, aminogroups, thiol groups, nitro groups, cyano groups, and the like.

Typically, the anti-viral organic acid will comprise from about 1 weightpercent to about 25 weight percent of lotion composition. As usedherein, a “virucidal effective amount” for each compound will depend onthe efficacy of the virucide. One possible way to measure the effectiveamount of a virucide is the amount sufficient to inactivate 99 percent(2 log drop) of rhinovirus type 16 within 10 minutes. A suitable methodfor testing virucidal efficacy is the Virucidal Assay Proceduredisclosed in U.S. Pat. No. 4,897,304, which is incorporated herein byreference. However, those skilled in the art of virology will recognizeother suitable test procedures for this purpose.

2. Topical Delivery System

The topical delivery system (or emollient) of the present inventionfunctions to incorporate the anti-viral organic acids into the lotionformulation, controls their delivery, and maintains them in the stratumcorneum. This reduces the amount of acid necessary for efficacy, andthereby reduces the potential for irritation.

The topical delivery systems of the present invention comprise one ormore polyesters. The polyesters of the present invention can be madefrom repeating monomeric units, as well as dimers, trimers, ortetramers.

Preferred polyesters include hydroxy-functional polyester diols andfatty alkyl capped complex polyesters. An especially preferredhydroxy-functional polyester diol is trimethylpentanediol/apidic acidcopolymer (CAS No. 26139-53-7), sold under the trade name LEXOREZ® TL-8,by the Inolex Chemical Co. of Philadelphia, Pa. An especially preferredfatty alkyl capped complex polyester is trimethylpentanediol/adipicisononanoic acid copolymer (CAS NO. 200512-90-9), sold under the tradename LEXOREZ® TC-8, also by the Inolex Chemical Co.

Preferably, the topical delivery system will comprise from about 5weight percent to about 25 weight percent of lotion composition.

3. Surfactant

The lotion compositions of the present invention may also contain aconditioning surfactant. The surfactants function to condition the skinwhile aiding in the inactivation of certain respiratory viruses.

Preferred cationic surfactants are quaternary ammonium compounds. Morepreferred cationic surfactants having the general formula:

wherein R₁, R₂, R₃, R₄ are independently selected from branched orstraight chain, saturated or unsaturated C₁-C₆ or C₁₄-C₂₄ compounds. Nomore than three of R₁, R₂, R₃, and R₄ may be a C₁-C₆ alkyl. R₃ and R₄may comprise a ring structure.

Especially preferred cationic surfactants include stearalkoniumchloride; methyl-1-(C₁₂-C₂₄) amido ethyl-2-(C₁₂-C₂₄) imidazoliniummethyl sulfates; C₁₂-C₂₄ quaternized esteramines; di (C₁-C₆ alkyl) di(C₁₂-C₂₄ alkyl) quaternary ammonium methyl sulfates; and polyquaternarycationic compounds.

Preferably, the cationic surfactant will comprise from about 1 weightpercent to about 25 weight percent of lotion composition.

4. Irritation Inhibiting Agents

The lotion compositions of the present invention may also contain anirritation inhibiting agent. The irritation inhibiting agents functionto soothe the skin that may be irritated by the other lotion components.

Preferred irritation inhibiting agents include strontium compounds andsilicone glycols. Especially preferred strontium compounds include Sr²⁺in combination with appropriate counter anions. Inorganic anionsinclude, but are not limited to, nitrate, halogens (particularly F, Cl,Br and I), carbonate, bicarbonate, hydroxide, oxide, peroxide, nitrite,sulfide, bisulfate, persulfate, glycero-phosphate, hypophosphate, borateand titanate. Examples of potentially suitable organic anions includecarboxylic acids, alkoxylates, amino acids, peptides, saturated andunsaturated organic acids, and saturated and unsaturated fatty acids.Particular examples include citrate, oxalate, acetate, gluconate,lactate, tartrate, maleate, benzoate, propionate, salicylate, ascorbate,formate, suc-cinate, folinate, aspartate, phthalate, oleate, palmitate,stearate, lauryl sulfate, lanolate, myristate, behenate, caseinate,cyclamate, pantothenate, EDTA and other polyaminopolycarboxylates,saccharin, thioglycolate, laurate, methylparaben, propylparaben, andricinoleate andsorbate anions.

Preferably, the irritation inhibiting agents will be present inconcentrations from about 5.0 mM to about 3000 mM of lotion composition.

5. Additives

The lotion composition may contain other conventional additives, such asoils, waxes, fatty alcohols, humectants, and the like.

The oils in the lotion composition serve as a carrier for thecomposition and to enhance skin barrier function. The amount of oil inthe composition can be from about 1 to about 95 weight percent. Suitableoils include, but are not limited to, the following classes of oils:petroleum or mineral oils, such as mineral oil and petrolatum; animaloils, such as mink oil and lanolin oil; plant oils, such as aloeextract, sunflower oil and avocado oil; and silicone oils, such asdimethicone and alkyl methyl silicones.

The waxes in the lotion composition function as a melting point controland to restrain lotion composition on the surface of the substrate. Theamount of wax in the composition can be from about 5 to about 95 weightpercent. Suitable waxes include, but are not limited to the followingclasses: natural waxes, such as beeswax and carnauba wax; petroleumwaxes, such as paraffin and ceresine wax; silicone waxes, such as alkylmethyl siloxanes; or synthetic waxes, such as synthetic beeswax andsynthetic sperm wax.

The fatty alcohols in the lotion compositions function to enhance thefeel of the lotion and to enhance the lotion's transfer abilities. Theamount of fatty alcohol in the composition, if present, can be fromabout 5 to about 40 weight percent. Suitable fatty alcohols includealcohols having a carbon chain length of C₁₄-C₃₀, including cetylalcohol, stearyl alcohol, and dodecyl alcohol.

The humectants in the lotion composition function to stabilize themoisture content of the tissue in the presence of fluctuating humidity.The water-soluble humectant can be any such material or compound whichcan be applied to the tissue web in a uniform manner, as by spraying,coating, dipping or printing, etc., and which possesses hygroscopic orhumectant properties and which will not interfere with the virucidaleffectiveness of the tissue product to the extent that the tissueproduct is no longer virucidally effective. Examples of suitablewater-soluble humectants include: polyglycols (as hereinafter defined),propylene glycol, sorbitol, lactic acid, sodium lactate, glycerol, andethoxylated castor oil.

Polyglycols, which for purposes herein include esters or ethers ofpolyglycols, having a weight average molecular weight of from about 75to about 90,000 are suitable for purposes of this invention. Thismolecular weight range represents physical states ranging from a lowviscosity liquid to a soft wax to a fairly hard solid. The highermolecular weight polyglycols naturally have to be melted in order to beapplied to a tissue web. Examples of suitable polyglycols includepolyethylene glycol, polypropylene glycol, polyoxypropylene adducts ofglycerol, methoxypolyethylene glycol, polyethylene glycol ethers ofsorbitol, polyethylene glycol ethers of glycerol, polyethylene glycolethers of stearic acid, polyethylene glycol ethers of lauryl alcohol,citric acid fatty esters, malic acid fatty esters, polyethylene glycolethers of oleyl alcohol, and ethoxylated stearate esters of sorbitol.Polyethylene glycol is a preferred polyglycol because it can be appliedto the tissue in amounts which are effective in improving softnesswithout leaving a noticeable residue on the consumer's hands.Polypropylene glycol is also effective, but tends to leave more of aresidue at equivalent amounts and is more hydrophobic than polyethyleneglycol.

The amount of water-soluble humectant in a single ply or web of a tissueproduct of this invention can be about 0.05 to weight percent orgreater. The weight percentage amount can vary greatly, depending uponthe desired tactile properties, the amount of carboxylic acid presentthat needs to be counteracted, the properties of the water-solublehumectant itself, etc. At water-soluble humectant levels greater thanabout 20 weight percent, the tissue product becomes soggy andunacceptable for normal tissue usage. More preferably, the amount ofpolyglycol in a single ply or web of a tissue product can be from about2 to about 6 weight percent.

In order to better enhance the benefits to consumers, additionalingredients can be used. The classes of ingredients and theircorresponding benefits include, without limitation, vitamins (topicalmedicinal benefits); dimethicone (skin protection); powders (lubricity,oil absorption, skin protection); preservatives and antioxidants(product integrity); ethoxylated fatty alcohols; (wetability, processaids); fragrance (consumer appeal); lanolin derivatives (skinmoisturization), colorants, optical brighteners, sunscreens, alphahydroxy acids, natural herbal extracts, and the like.

Production

For purposes herein, “tissue products” are those paper productscomprising one or more creped cellulosic webs or plies. Cellulosic webssuitable for use in the product of this invention include those websuseful for facial tissues, bathroom tissues, table napkins and papertowels. This includes webs having basis weights of from about 5 to about30 pounds per 2880 square feet. It also includes webs containing asubstantial proportion of synthetic fibers as well as webs which aresubstantially solely made of cellulose papermaking fibers.

The anti-viral lotion composition may be applied to the tissue productby any of the methods known in the art such as gravure printing,flexographic printing, spraying, WEKO, slot die coating, orelectrostatic spraying. The preferred application methods arerotogravure printing methods, such as disclosed in commonly assignedcopending U.S. Ser. No. 60/174,087, “Germicidal Tissue Product UsingRotogravure Rolls”, filed on Dec. 30, 1999, or in U.S. Pat. No.5,665,426, issued to Krzysik et al., both of which are incorporatedherein by reference in their entireties.

In one preferred method of making an anti-viral tissue product, thelotion composition includes one or more anti-viral organic acids, onemore polyesters, and one or more oils and/or one or more waxes, and hasa melting point from about 30° C. to about 70° C. The lotion compositionis heated until it melts, and then is uniformly applied one or moresurfaces of a tissue web in spaced-apart deposits. The composition isthen resolidified by cooling. The tissue web may be cooled before orafter the deposits of the coating composition are applied in order toaccelerate solidification of the deposits.

Preferred lotion add-on is in the range of 1% to 40% of total tissueweight, more specifically from about 5 to about 25 weight percent, andstill more specifically from about 10 to about 15 weight percent. Theadd-on amount will depend upon the desired effect of the composition onthe product attributes and the specific composition.

The surface area coverage of the composition is preferably uniform oversubstantially all of the tissue surface, but only partially covers thesurface(s) of the tissue product. This is achieved by a large number ofsmall spaced-apart deposits which, when viewed by the naked eye, appearto cover the entire surface, but in fact do not. The actual surface areacoverage of the deposits can be from about 30 to about 99 percent, morespecifically from about 50 to about 80 percent. (“Surface area” is thearea of a simple plan view of the tissue, not taking into account thethree-dimensional topography of the tissue which would otherwiseincrease the surface area value for any given tissue sample). Byproviding a large number of very small deposits, the penetration of thecomposition can be more easily controlled to substantially remain on ornear the surface of the tissue.

The invention will be further illustrated with reference to thefollowing specific example. It is understood that the example is givenby way of illustration and is not meant to limit the disclosure or theclaims that follow.

EXAMPLE

An antiviral lotion composition having the following components wasprepared: Component Weight Percent Water 5.0 Citric Acid 1.0Methyl-1-Oleyl Amido Ethyl-2-Oleyl 2.0 Imidazolinium Methyl Sulfate, 90%solids in propylene glycol Lexorez TL-8 10.0 Mineral Oil 49.04Dimethicone, 100 cSt 0.82 Isopropropyl Palmitate 2.46 Ceresin Wax 14.76Stearyl Alcohol 14.76 Aloe Extract 0.08 Vitamin E Acetate 0.08

The components were first grouped into two phases. Phase A contained thewater, citric acid, methyl-1-oleyl amido ethyl-2-oleyl imidazoliniummethyl sulfate, and Lexorez TL-8. Phase B contained the remainingcomponents.

Phase A was prepared by adding the citric acid to the water, and themixture was stirred until the citric acid dissolved. The methyl-1-oleylamido ethyl-2-oleyl imidazolinium methyl sulfate was then added to themixture and the new mixture was again stirred until dissolved. Finally,Lexorez TL-8 was added to the mixture, and the mixture was stirred untiluniform.

Phase B was prepared by first adding the dimethicone to the isopropylpalmitate and stirring until the mixture was well dispersed. The mineraloil was heated to 60° C., and the dimethicone/isopropyl palmitatemixture was then added to the hot mineral oil and mixed until welldispersed. Ceresin wax was added to the batch and mixed until melted.Stearyl alcohol was then added to the batch and mixed until melted. Thealoe extract and vitamin E acetate were then added and mixed until welldispersed.

With Phase B at a temperature of 60-65° C., Phase A was slowly added toPhase B with constant stirring. After thorough mixing, the compositionwas cooled to room temperature. The resulting composition was a uniform,soft, waxy, anti-viral solid, suitable for application to a tissuesubstrate.

It should be readily understood by those persons skilled in the art thatthe present invention is susceptible of a broad utility and application.Many embodiments and adaptations of the present invention other thanthose herein described, as well as many variations, modifications andequivalent arrangements will be apparent from or reasonably suggested bythe present invention and the foregoing description thereof, withoutdeparting from the substance or scope of the present invention.

Accordingly, while the present invention has been described herein indetail in relation to several embodiments, it is to be understood thatthis disclosure is only illustrative and exemplary of the presentinvention and is made merely for purposes of providing a full andenabling disclosure of the invention. The foregoing disclosure is notintended or to be construed to limit the present invention or otherwiseto exclude any such other embodiments, adaptations, variations,modifications and equivalent arrangements, the present invention beinglimited only by the claims appended hereto and the equivalents thereof.

1. A non-irritating anti-viral lotioned tissue product having applied toat least one surface thereof an anti-viral lotion compositioncomprising: a virucidal effective amount of at least one anti-viralorganic acid; a topical delivery system including at least onehydroxy-functional polyester diol.
 2. The lotioned tissue product ofclaim 1, wherein said lotion composition comprises from about 1% toabout 25% of said anti-viral organic acid.
 3. The lotioned tissueproduct of claim 2, wherein said at least one anti-viral organic acidcomprises at least one member from the group consisting of carboxylicacids having the structure R—COOH, wherein R is a C₁-C₆ alkyl; C₁-C₆alkyl carboxy; C₁-C₆ alkyl carboxyhydroxy; C₁-C₆ alkyl carboxy halo;C₁-C₆ alkylcarboxy dihydroxy; C₁-C₆ alkyl dicarboxyhydroxy; C₁-C₆alkenyl; C₁-C₆ alkenyl carboxy; C₁-C₆ alkenyl phenyl; or substitutedphenyl radical.
 4. The lotioned tissue product of claim 3, wherein oneor more hydrogen atoms of R is substituted with a functional groupselected from the group consisting of halogen atoms, hydroxyl groups,amino groups, thiol groups, nitro groups, and cyano groups.
 5. Thelotioned tissue product of claim 3, wherein said at least one anti-viralacid is selected from the group consisting of citric acid, malic acid,adipic acid, glutaric acid, succinic acid, and mixtures thereof.
 6. Thelotioned tissue product of claim 2, wherein said at least onehydroxy-functional polyester diol comprises trimethylpentanediol/apidicacid copolymer.
 7. The lotioned tissue product of claim 1, wherein thelotion composition further comprises a surfactant.
 8. A lotioned tissueproduct having applied to at least one surface thereof an anti-virallotion composition comprising: about 1% to about 25% of at least oneanti-viral organic acid; about 5% to about 25% of an emollient includingat least one hydroxyl-functional polyester diol; and a cationicsurfactant.
 9. The lotioned tissue product of claim 8, wherein saidcationic surfactant comprises a quaternary ammonium compound.
 10. Anon-irritating, anti-viral lotion composition comprising: a virucidaleffective amount of at least one anti-viral organic acid; and a topicaldelivery system including at least one hydroxyl-functional polyesterdiol.
 11. The lotion composition of claim 10, wherein said lotioncomposition comprises from about 1% to about 25% of said anti-viralorganic acid.
 12. The lotion composition of claim 11, wherein said atleast one anti-viral organic acid comprises at least one member from thegroup consisting of carboxylic acids having the structure R—COOH,wherein R is a C₁-C₆ alkyl; C₁-C₆ alkyl carboxy; C₁-C₆ alkylcarboxyhydroxy; C₁-C₆ alkyl carboxy halo; C₁-C₆ alkylcarboxy dihydroxy;C₁-C₆ alkyl dicarboxyhydroxy; C₁-C₆ alkenyl; C₁-C₆ alkenyl carboxy;C₁-C₆ alkenyl phenyl; or substituted phenyl radical.
 13. The lotioncomposition of claim 12, wherein one or more hydrogen atoms of R issubstituted with a functional group selected from the group consistingof halogen atoms, hydroxyl groups, amino groups, thiol groups, nitrogroups, and cyano groups.
 14. The lotion composition of claim 12,wherein said at least one anti-viral acid is selected from the groupconsisting of citric acid, malic acid, adipic acid, glutaric acid,succinic acid, and mixtures thereof.
 15. The lotion composition of claim11, wherein said at least one hydroxy-functional polyester diolcomprises trimethylpentanediol/apidic acid copolymer.
 16. The lotioncomposition of claim 10, wherein the lotion composition furthercomprises a surfactant.
 17. The lotion composition of claim 16, whereinsaid surfactant comprises a cationic surfactant.
 18. An anti-virallotion composition comprising: about 1% to about 25% of at least oneanti-viral organic acid; about 5% to about 25% of an emollient includingat least one hydroxyl-functional polyester diol; and a cationicsurfactant.
 19. The lotion composition of claim 18, wherein saidcationic surfactant comprises a quaternary ammonium compound.
 20. Amethod of inhibiting the transfer of a viral infection comprising:providing anti-viral lotion tissue product having applied to at leastone surface thereof an anti-viral lotion composition comprising avirucidal effective amount of at least one anti-viral organic acid and atopical delivery system including at least one hydroxyl-functionalpolyester diol; contacting a fluid containing at least one virus withsaid anti-viral tissue product; and absorbing said fluid within saidabsorbent article to contact the fluid with said anti-viral lotioncomposition.
 21. The method of claim 20, further comprising:transferring a portion of the lotion composition to the user of thetissue product.
 22. A method of making an anti-viral tissue productcomprising: heating a composition comprising an a virucidal effectiveamount of at least one anti-viral organic acid at least onehydroxy-functional polyester diol, at least one oil and at least one waxto a temperature above the melting point of the composition, causingsaid composition to melt, said composition having a melting point offrom about 30° C. to about 70° C.; uniformly applying the meltedcomposition to at least one surface of a tissue web in spaced-apartdeposits; and resolidifying the deposits of the melted composition. 23.The method of claim 22 wherein the heated composition is applied to thetissue web with a gravure printer.
 24. The method of claim 22 whereinthe tissue web is cooled before or after the deposits of the coatingcomposition are applied in order to accelerate solidification of thedeposits.
 25. The method of claim 22 wherein the tissue product is afacial tissue.